NVCT
Nuvectis Pharma, Inc.- Healthcare
- Biotechnology
- $655M market cap
Forecast run · Oct 29, 2026Upside rank 219 of 3,186
Model Signal
ForecastQ Daily Probabilities
54.8%
53.3%
51.1%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$20.05
Price target$37.33
Implied move+86.2%
Analysts3
ForecastQ Portfolios
NVCT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.